
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2486028/publications.pdf Version: 2024-02-01



DETED A DINTO

#	Article	IF	CITATIONS
1	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. European Urology Oncology, 2022, 5, 176-186.	2.6	24
2	Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?. Journal of Urology, 2022, 207, 95-107.	0.2	29
3	A Cascaded Deep Learning–Based Artificial Intelligence Algorithm for Automated Lesion Detection and Classification on Biparametric Prostate Magnetic Resonance Imaging. Academic Radiology, 2022, 29, 1159-1168.	1.3	21
4	Reply by Authors. Journal of Urology, 2022, 207, 106-107.	0.2	0
5	Deep learning-based artificial intelligence for prostate cancer detection at biparametric MRI. Abdominal Radiology, 2022, 47, 1425-1434.	1.0	18
6	Development of a 3D CNN-based AI Model for Automated Segmentation of the Prostatic Urethra. Academic Radiology, 2022, 29, 1404-1412.	1.3	9
7	Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance Journal of Clinical Oncology, 2022, 40, 249-249.	0.8	0
8	Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology. Journal of Clinical Oncology, 2022, 40, 1583-1589.	0.8	14
9	Assessment of Aortoiliac Atherosclerotic Plaque on CT in Prostate Cancer Patients Undergoing Treatment. Tomography, 2022, 8, 607-616.	0.8	0
10	Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. Urology, 2022, 165, 170-177.	0.5	2
11	Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2022, , .	0.2	2
12	Atherosclerotic Plaque Burden on Abdominal CT: Automated Assessment With Deep Learning on Noncontrast and Contrast-enhanced Scans. Academic Radiology, 2021, 28, 1491-1499.	1.3	22
13	Quality of Prostate MRI: Is the PI-RADS Standard Sufficient?. Academic Radiology, 2021, 28, 199-207.	1.3	44
14	Role of multiparametric prostate MRI in the management of prostate cancer. World Journal of Urology, 2021, 39, 651-659.	1.2	24
15	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. Clinical Cancer Research, 2021, 27, 429-437.	3.2	22
16	Quantitative Characterization of the Prostatic Urethra Using MRI: Implications for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia. Academic Radiology, 2021, 28, 664-670.	1.3	4
17	Metastasectomy for rectal wall seeding of prostate adenocarcinoma after transrectal prostate biopsy. Urology Case Reports, 2021, 34, 101445.	0.1	0
18	Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance. European Urology Oncology, 2021, 4, 227-234.	2.6	14

#	Article	IF	CITATIONS
19	Bilateral disease and risk of prostate cancer progression in an active surveillance cohort Journal of Clinical Oncology, 2021, 39, 207-207.	0.8	Ο
20	Considerations for active surveillance in select Gleason grade group 2 patients: A preliminary study Journal of Clinical Oncology, 2021, 39, 206-206.	0.8	0
21	MRI-guided fusion biopsy of the prostate resection bed among post-radical prostatectomy patients with rising PSA Journal of Clinical Oncology, 2021, 39, 208-208.	0.8	0
22	â€~Case of the Month' from the National Cancer Institute, Bethesda, MD, USA: investigating genetic aberrations in a patient with highâ€risk prostate cancer. BJU International, 2021, 127, 171-174.	1.3	0
23	Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers. Scientific Reports, 2021, 11, 5662.	1.6	2
24	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. European Urology, 2021, 80, 746-757.	0.9	50
25	Magnetic Resonance Imaging-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer. Journal of Urology, 2021, 205, 1352-1360.	0.2	3
26	Reply by Authors. Journal of Urology, 2021, 205, 1359-1360.	0.2	0
27	MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up. Diagnostic and Interventional Radiology, 2021, 27, 394-400.	0.7	9
28	Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens. Radiology, 2021, 299, 613-623.	3.6	11
29	The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy. Journal of Urology, 2021, 206, 1157-1165.	0.2	10
30	Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 519-528.	2.6	10
31	The Importance of Quality in Prostate MRI. Seminars in Roentgenology, 2021, 56, 384-390.	0.2	6
32	Ablation of Low-Risk Prostate Cancer: Both Sides of the Story. Journal of Endourology, 2021, 35, 1288-1289.	1.1	0
33	Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 729.e1-729.e6.	0.8	6
34	Making a case "for―focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials. World Journal of Urology, 2021, 39, 729-739.	1.2	7
35	A Pilot Study of Dynamic 18F-DCFPyL PET/CT Imaging of Prostate Adenocarcinoma in High-Risk Primary Prostate Cancer Patients. Molecular Imaging and Biology, 2021, , 1.	1.3	9
36	MRI-guided Biopsy in Active Surveillance of Prostate Cancer. Journal of Urology, 2021, , 101097JU000000000002343.	0.2	2

#	Article	IF	CITATIONS
37	Emerging role for local therapy in oligometastatic prostate cancer. Clinical Advances in Hematology and Oncology, 2021, 19, 460-467.	0.3	1
38	Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. American Journal of Roentgenology, 2020, 214, 105-113.	1.0	17
39	Apical periurethral transition zone lesions: MRI and histology findings. Abdominal Radiology, 2020, 45, 3258-3264.	1.0	0
40	¹⁸ F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy. Journal of Nuclear Medicine, 2020, 61, 881-889.	2.8	38
41	Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy. International Urology and Nephrology, 2020, 52, 633-638.	0.6	1
42	Prospective Evaluation of ¹⁸ F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. American Journal of Roentgenology, 2020, 215, 652-659.	1.0	22
43	Multicenter Multireader Evaluation of an Artificial Intelligence–Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. American Journal of Roentgenology, 2020, 215, 903-912.	1.0	29
44	Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer. Urology, 2020, 144, 164-170.	0.5	4
45	Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: a critical review. Translational Andrology and Urology, 2020, 9, 1415-1427.	0.6	9
46	Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection. American Journal of Roentgenology, 2020, 215, 1098-1103.	1.0	17
47	Local failure after definitive radiation treatment of lymph-node positive prostate cancer: supporting the use of novel imaging techniques to personalize treatment options. BJR case Reports, 2020, 6, 20200001.	0.1	0
48	Deepâ€Learningâ€Based Artificial Intelligence for <scp>Plâ€RADS</scp> Classification to Assist Multiparametric Prostate <scp>MRI</scp> Interpretation: A Development Study. Journal of Magnetic Resonance Imaging, 2020, 52, 1499-1507.	1.9	52
49	Deep Learning Framework for Epithelium Density Estimation in Prostate Multi-Parametric Magnetic Resonance Imaging. , 2020, , .		2
50	Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. European Urology, 2020, 78, 371-378.	0.9	66
51	Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2020, 10, 326-339.	1.1	7
52	A case report of multiple primary prostate tumors with differential drug sensitivity. Nature Communications, 2020, 11, 837.	5.8	28
53	MRI-guided pelvic lymph node biopsy via transrectal approach in prostate cancer. Urology Case Reports, 2020, 30, 101129.	0.1	0
54	Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. Urology, 2020, 140, 85-90.	0.5	15

#	Article	IF	CITATIONS
55	Impact of bowel preparation with Fleet's™ enema on prostate MRI quality. Abdominal Radiology, 2020, 45, 4252-4259.	1.0	26
56	Use of multiparametric magnetic resonance imaging (mpMRI) in localized prostate cancer. Expert Review of Medical Devices, 2020, 17, 435-442.	1.4	9
57	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. , 2020, 8, e000655.		41
58	microRNA Expression Profiling in Young Prostate Cancer Patients. Journal of Cancer, 2020, 11, 4106-4114.	1.2	32
59	Rapid perceptual processing in two- and three-dimensional prostate images. Journal of Medical Imaging, 2020, 7, 1.	0.8	7
60	A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures Journal of Clinical Oncology, 2020, 38, 368-368.	0.8	0
61	Tracked Foley catheter for motion compensation during fusion image-guided prostate procedures: a phantom study. European Radiology Experimental, 2020, 4, 24.	1.7	0
62	Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients Journal of Clinical Oncology, 2020, 38, e17567-e17567.	0.8	1
63	PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance. Journal of Urology, 2020, 204, 1229-1235.	0.2	5
64	Does size matter? Lesion size as an indicator of number of cores needed to detect clinically significant prostate cancer Journal of Clinical Oncology, 2020, 38, 283-283.	0.8	0
65	Pathologic outcomes of MRI invisible tumors in prostate cancer Journal of Clinical Oncology, 2020, 38, 282-282.	0.8	0
66	Multiple primary prostate tumors with differential drug sensitivity Journal of Clinical Oncology, 2020, 38, 342-342.	0.8	0
67	Association of PI-RADS categories and PSA density with active surveillance progression in patients with prostate cancer Journal of Clinical Oncology, 2020, 38, 293-293.	0.8	0
68	Focal therapy for prostate cancer: recent advances and future directions. Clinical Advances in Hematology and Oncology, 2020, 18, 116-125.	0.3	3
69	Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?. World Journal of Urology, 2019, 37, 235-241.	1.2	31
70	Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches. World Journal of Urology, 2019, 37, 419-427.	1.2	9
71	Contemporary treatments in prostate cancer focal therapy. Current Opinion in Oncology, 2019, 31, 200-206.	1.1	68
72	A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. Radiology, 2019, 290, 709-719.	3.6	140

#	Article	IF	CITATIONS
73	National Survey of Patterns Employing Targeted MRI/US Guided Prostate Biopsy in the Diagnosis and Staging of Prostate Cancer. Current Urology, 2019, 12, 97-103.	0.4	19
74	Index tumor volume on MRI as a predictor of clinical and pathologic outcomes following radical prostatectomy. International Urology and Nephrology, 2019, 51, 1349-1355.	0.6	8
75	Use of multiparametric <scp>magnetic resonance imaging</scp> and fusionâ€guided biopsies to properly select and follow Africanâ€American men on active surveillance. BJU International, 2019, 124, 768-774.	1.3	8
76	The role of multiparametric MRI in biopsy-naive prostate cancer. Nature Reviews Urology, 2019, 16, 276-277.	1.9	10
77	Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI. American Journal of Roentgenology, 2019, 212, 1197-1205.	1.0	75
78	Intra―and interreader reproducibility of Plâ€RADSv2: A multireader study. Journal of Magnetic Resonance Imaging, 2019, 49, 1694-1703.	1.9	102
79	Learning deep similarity metric for 3D MR–TRUS image registration. International Journal of Computer Assisted Radiology and Surgery, 2019, 14, 417-425.	1.7	101
80	Template for MR Visualization and Needle Targeting. Annals of Biomedical Engineering, 2019, 47, 524-536.	1.3	5
81	Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 182.e1-182.e8.	0.8	10
82	A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI). Academic Radiology, 2019, 26, 5-14.	1.3	12
83	Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy. Journal of Urology, 2019, 201, 84-90.	0.2	24
84	When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion of Prostate Cancer. Journal of Urology, 2019, 201, 943-949.	0.2	5
85	Fully automated prostate whole gland and central gland segmentation on MRI using holistically nested networks with short connections. Journal of Medical Imaging, 2019, 6, 1.	0.8	14
86	A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy. Turkish Journal of Urology, 2019, 45, 357-365.	1.3	18
87	One and done?: Utility of PSA density as a predictor of number of cores needed to detect clinically significant prostate cancer Journal of Clinical Oncology, 2019, 37, 104-104.	0.8	Ο
88	MRI-TRUS fusion-guided biopsy in obese patients: Does it reduce risk of prostate cancer upgrade on final pathology compared to systematic 12-core biopsy?. Journal of Clinical Oncology, 2019, 37, 110-110.	0.8	1
89	MRI targeted biopsy dramatically increases detection of clinically significant prostate cancer while reducing the risk of indolent cancer detection Journal of Clinical Oncology, 2019, 37, 108-108.	0.8	0
90	A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncology, 2018, 4, 678.	3.4	141

#	Article	IF	CITATIONS
91	Prospective comparison of Plâ€RADS version 2 and qualitative inâ€house categorization system in detection of prostate cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 1326-1335.	1.9	18
92	Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. European Radiology, 2018, 28, 4407-4417.	2.3	68
93	Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology—Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?. Journal of Urology, 2018, 199, 976-982.	0.2	89
94	All over the map: An interobserver agreement study of tumor location based on the Plâ€RADSv2 sector map. Journal of Magnetic Resonance Imaging, 2018, 48, 482-490.	1.9	31
95	Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase) Tj ETQq1	1_0.78433 1.1	l4grgBT /O∨
96	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	13.9	2,036
97	What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology, 2018, 286, 186-195.	3.6	188
98	Clinical impact of PSMA-based 18F–DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 4-11.	3.3	57
99	Ruling out clinically significant prostate cancer with negative multi-parametric MRI. International Urology and Nephrology, 2018, 50, 7-12.	0.6	19
100	MRI to guide biopsies or avoid biopsies?. Current Opinion in Urology, 2018, 28, 522-528.	0.9	3
101	Sentinel lymph node imaging in urologic oncology. Translational Andrology and Urology, 2018, 7, 887-902.	0.6	21
102	"Super-active surveillance― MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer. Gland Surgery, 2018, 7, 166-187.	0.5	17
103	Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagnostic and Interventional Radiology, 2018, 24, 46-53.	0.7	21
104	Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience. Diagnostic and Interventional Radiology, 2018, 24, 316-320.	0.7	12
105	Comparison of Elastic and Rigid Registration during Magnetic Resonance Imaging/Ultrasound Fusion-Guided Prostate Biopsy: A Multi-Operator Phantom Study. Journal of Urology, 2018, 200, 1114-1121.	0.2	18
106	Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer. Radiology, 2018, 288, 485-491.	3.6	53
107	Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 341.e1-341.e7.	0.8	23
108	Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15Âmm the best threshold?. Abdominal Radiology, 2018, 43, 3436-3444.	1.0	13

#	Article	IF	CITATIONS
109	Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems. American Journal of Roentgenology, 2018, 211, W33-W41.	1.0	26
110	Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer. Journal of Urology, 2018, 200, 1041-1047.	0.2	66
111	Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy Journal of Clinical Oncology, 2018, 36, 5083-5083.	0.8	2
112	Neoadjuvant enzalutamide and androgen deprivation therapy for high-risk prostate cancer: Early results from a feasibility trial Journal of Clinical Oncology, 2018, 36, 94-94.	0.8	1
113	Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation. Oncotarget, 2018, 9, 33804-33817.	0.8	65
114	Active surveillance of prostate cancer in African-Americans during the MRI era Journal of Clinical Oncology, 2018, 36, 108-108.	0.8	0
115	Are all biopsies created equal? comparison of extended sextant prostate biopsies performed with and without MRI-TRUS fusion biopsy system Journal of Clinical Oncology, 2018, 36, 117-117.	0.8	0
116	Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses Journal of Clinical Oncology, 2018, 36, 5082-5082.	0.8	0
117	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force. European Urology, 2017, 71, 648-655.	0.9	190
118	Encountering "Dropped―Gallstones During Robotic-assisted Laparoscopic Radical Prostatectomy. Urology, 2017, 103, e11-e12.	0.5	1
119	Detection of prostate cancer in multiparametric MRI using random forest with instance weighting. Journal of Medical Imaging, 2017, 4, 024506.	0.8	33
120	Prospective Evaluation of PI-RADSâ,,¢ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. Journal of Urology, 2017, 198, 583-590.	0.2	127
121	Effect of Prostate Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy on Radiation Treatment Recommendations. International Journal of Radiation Oncology Biology Physics, 2017, 97, 947-951.	0.4	4
122	Current Role of Magnetic Resonance Imaging in Prostate Cancer. Current Radiology Reports, 2017, 5, 1.	0.4	1
123	Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. Radiology, 2017, 285, 859-869.	3.6	126
124	Current beliefs and practice patterns among urologists regarding prostate magnetic resonance imaging and magnetic resonance–targeted biopsy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 32.e1-32.e7.	0.8	30
125	Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdominal Radiology, 2017, 42, 346-349.	1.0	8
126	Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. Journal of Urology, 2017, 197, 327-334.	0.2	84

#	Article	IF	CITATIONS
127	Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 30.e1-30.e8.	0.8	42
128	Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. Journal of Urology, 2017, 197, 640-646.	0.2	90
129	Robotic System for MRI-Guided Focal Laser Ablation in the Prostate. IEEE/ASME Transactions on Mechatronics, 2017, 22, 107-114.	3.7	39
130	Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study. Journal of Magnetic Resonance Imaging, 2017, 45, 579-585.	1.9	170
131	Optimal high b-value for diffusion weighted MRI in diagnosing high risk prostate cancers in the peripheral zone. Journal of Magnetic Resonance Imaging, 2017, 45, 125-131.	1.9	38
132	Should Hypoechoic Lesions on Transrectal Ultrasound Be Sampled During Magnetic Resonance Imaging-targeted Prostate Biopsy?. Urology, 2017, 105, 113-117.	0.5	12
133	Correlation between ERG Fusion Protein and Androgen Receptor Expression by Immunohistochemistry in Prostate, Possible Role in Diagnosis and Therapy. Journal of Cancer, 2017, 8, 2604-2613.	1.2	8
134	Prostate Cancer: A Correlative Study of Multiparametric MR Imaging and Digital Histopathology. Radiology, 2017, 285, 147-156.	3.6	33
135	National survey of practice patterns employing MRI-guided prostate biopsy for diagnosis of prostate cancer Journal of Clinical Oncology, 2017, 35, 104-104.	0.8	3
136	Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation Journal of Clinical Oncology, 2017, 35, 30-30.	0.8	2
137	Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer. Balkan Medical Journal, 2017, 34, 388-396.	0.3	5
138	Can index lesion tumor volume on T2 weighted MRI predict biochemical recurrence following radical prostatectomy?. Journal of Clinical Oncology, 2017, 35, 32-32.	0.8	0
139	Training and skills assessment for MRI/TRUS fusion-guided prostate biopsy: End-fire vs. side-fire ultrasound probes Journal of Clinical Oncology, 2017, 35, e540-e540.	0.8	0
140	Comparison of multiparametric MRI to PSA kinetics as an indication of prostate cancer progression in men on active surveillance Journal of Clinical Oncology, 2017, 35, 59-59.	0.8	0
141	Index lesion tumor volume on MRI to predict adverse pathologic outcomes following radical prostatectomy Journal of Clinical Oncology, 2017, 35, 43-43.	0.8	0
142	Focal therapy for prostate cancer: Attitude and practice patterns Journal of Clinical Oncology, 2017, 35, e541-e541.	0.8	0
143	Changes in prostate cancer detection rate of fusion versus systematic biopsy over time: A single center experience Journal of Clinical Oncology, 2017, 2017, 15-15.	0.8	0
144	A model for predicting focal ablation candidates in patients with prostate cancer based on MRI and biopsy criteria Journal of Clinical Oncology, 2017, 35, 31-31.	0.8	0

#	Article	IF	CITATIONS
145	Changes in prostate cancer detection rate of fusion versus systematic biopsy over time: A single center experience Journal of Clinical Oncology, 2017, 35, 15-15.	0.8	0
146	Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification. International Urology and Nephrology, 2016, 48, 1445-1452.	0.6	9
147	Robot for Magnetic Resonance Imaging Guided Focal Prostate Laser Ablation1. Journal of Medical Devices, Transactions of the ASME, 2016, 10, .	0.4	4
148	Editorial Comment. Journal of Urology, 2016, 195, 1427-1427.	0.2	0
149	A urologist's perspective on prostate cancer imaging: past, present, and future. Abdominal Radiology, 2016, 41, 805-816.	1.0	25
150	The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 254.e15-254.e21.	0.8	25
151	Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. Journal of the National Cancer Institute, 2016, 108, djw039.	3.0	68
152	Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. Journal of Urology, 2016, 196, 690-696.	0.2	116
153	Does Abstinence From Ejaculation Before Prostate MRI Improve Evaluation of the Seminal Vesicles?. American Journal of Roentgenology, 2016, 207, 1205-1209.	1.0	28
154	Application of an unsupervised multi-characteristic framework for intermediate-high risk prostate cancer localization using diffusion-weighted MRI. Magnetic Resonance Imaging, 2016, 34, 1227-1234.	1.0	4
155	Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. Ca-A Cancer Journal for Clinicians, 2016, 66, 326-336.	157.7	128
156	Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. International Urology and Nephrology, 2016, 48, 1817-1821.	0.6	18
157	Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncology, 2016, 12, 2417-2430.	1.1	20
158	Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. Journal of Urology, 2016, 196, 1613-1618.	0.2	305
159	Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. Pharmaceutical Research, 2016, 33, 2459-2469.	1.7	8
160	Lack of Impact of Robotic Assisted Laparoscopic Radical Prostatectomy on Intraoperative Levels of Prostate Cancer Circulating Tumor Cells. Journal of Urology, 2016, 195, 1136-1142.	0.2	14
161	Ferumoxytol as an intraprostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates. Acta Radiologica, 2016, 57, 1396-1401.	0.5	8
162	Prostate Cancer Diagnosis on Repeat Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling. Journal of Urology, 2016, 196, 62-67.	0.2	20

#	Article	IF	CITATIONS
163	Reproducibility of Multiparametric Magnetic Resonance Imaging and Fusion Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort. Journal of Urology, 2016, 195, 1737-1743.	0.2	18
164	Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes. Current Urology Reports, 2016, 17, 32.	1.0	61
165	Correlation of magnetic resonance imaging with digital histopathology in prostate. International Journal of Computer Assisted Radiology and Surgery, 2016, 11, 657-666.	1.7	22
166	DCE MRI of prostate cancer. Abdominal Radiology, 2016, 41, 844-853.	1.0	56
167	Evaluating the Role of mpMRI in Prostate Cancer Assessment. Expert Review of Medical Devices, 2016, 13, 129-141.	1.4	13
168	Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population. Urology, 2016, 88, 125-134.	0.5	81
169	Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. PLoS ONE, 2016, 11, e0157130.	1.1	5
170	Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy. PLoS ONE, 2016, 11, e0157313.	1.1	32
171	Expanded criteria in men on active surveillance monitored by MRI-TRUS fusion biopsy Journal of Clinical Oncology, 2016, 34, 115-115.	0.8	0
172	Tumor contact length: A novel multiparametric MRI predictor of prostate cancer outcomes Journal of Clinical Oncology, 2016, 34, 61-61.	0.8	0
173	Multi-institutional evaluation of multiparametric MRI and fusion-guided prostate biopsy in a biopsy-naive population Journal of Clinical Oncology, 2016, 34, 60-60.	0.8	0
174	Missing the mark? Prostate cancer upgrading by systematic biopsy over fusion biopsy Journal of Clinical Oncology, 2016, 34, 62-62.	0.8	0
175	MRIâ€based prostate volumeâ€adjusted prostateâ€specific antigen in the diagnosis of prostate cancer. Journal of Magnetic Resonance Imaging, 2015, 42, 1733-1739.	1.9	23
176	A Case of In-Bore Transperineal MRI-Guided Prostate Biopsy of a Patient with Ileal Pouch-Anal Anastomosis. Case Reports in Urology, 2015, 2015, 1-3.	0.1	7
177	Is Visual Registration Equivalent to Semiautomated Registration in Prostate Biopsy?. BioMed Research International, 2015, 2015, 1-7.	0.9	22
178	Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy. Abdominal Imaging, 2015, 40, 2557-2565.	2.0	34
179	Editorial Comment. Urology, 2015, 85, 429.	0.5	3
180	Clinical Implications of a Multiparametric Magnetic Resonance Imaging Based Nomogram Applied to Prostate Cancer Active Surveillance. Journal of Urology, 2015, 193, 1943-1949.	0.2	60

#	Article	IF	CITATIONS
181	Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting. European Urology, 2015, 67, 771-777.	0.9	206
182	The Role of Image Guided Biopsy Targeting in Patients with Atypical Small Acinar Proliferation. Journal of Urology, 2015, 193, 473-478.	0.2	30
183	A Phase I Dosing Study of Ferumoxytol for MR Lymphography at 3 T in Patients With Prostate Cancer. American Journal of Roentgenology, 2015, 205, 64-69.	1.0	57
184	Upgrading prostate cancer following proton beam therapy. Urology Annals, 2015, 7, 262.	0.3	1
185	Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology, 2015, 277, 741-750.	3.6	296
186	Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infectious Diseases, The, 2015, 15, 1167-1174.	4.6	216
187	Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 390.	3.8	1,267
188	Automated prostate cancer detection using <i>T</i> 2â€weighted and highâ€ <i>b</i> â€value diffusionâ€weighted magnetic resonance imaging. Medical Physics, 2015, 42, 2368-2378.	1.6	81
189	Magnetic Resonance Sentinel Lymph Node Imaging of the Prostate with Gadofosveset Trisodium–Albumin. Academic Radiology, 2015, 22, 646-652.	1.3	17
190	The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy. Journal of Urology, 2015, 194, 105-111.	0.2	56
191	Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e1-202.e7.	0.8	133
192	Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12–Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients. Journal of Endourology, 2015, 29, 1115-1121.	1.1	41
193	Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?. Abdominal Imaging, 2015, 40, 3222-3229.	2.0	22
194	Multiparametric magnetic resonance imaging-transrectal ultrasound fusion–assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 425.e1-425.e6.	0.8	32
195	Association of NaF PET/CT findings with PSA and alkaline phosphatase in untreated castration-sensitive prostate cancer Journal of Clinical Oncology, 2015, 33, 122-122.	0.8	0
196	Can mpMRI predict biochemical recurrence after radical prostatectomy? Implications for preoperative staging and surgical planning Journal of Clinical Oncology, 2015, 33, 161-161.	0.8	0
197	Performance of MRI-TRUS-guided fusion biopsy to detect progression on active surveillance for low- and intermediate-risk prostate cancer Journal of Clinical Oncology, 2015, 33, 43-43.	0.8	0
198	Ferumoxytol enhanced MRI for lymph node staging in prostate cancer Journal of Clinical Oncology, 2015, 33, 208-208.	0.8	1

#	Article	IF	CITATIONS
199	How reliable is a negative MRI/TRUS fusion biopsy? The predictive value of targeted biopsy for prostate cancer Journal of Clinical Oncology, 2015, 33, 51-51.	0.8	0
200	Magnetic resonance imaging-guided focal laser ablation for prostate cancer: A phase I trial Journal of Clinical Oncology, 2015, 33, e16128-e16128.	0.8	0
201	Multiparametric magnetic resonance imaging (<scp>MRI</scp>) and subsequent <scp>MRI</scp> /ultrasonography fusionâ€guided biopsy increase the detection of anteriorly located prostate cancers. BJU International, 2014, 114, E43-E49.	1.3	103
202	Multiparametric MRI in the PSA Screening Era. BioMed Research International, 2014, 2014, 1-6.	0.9	26
203	Whole Prostate Volume and Shape Changes with the Use of an Inflatable and Flexible Endorectal Coil. Radiology Research and Practice, 2014, 2014, 1-6.	0.6	8
204	Multiparametric MRI in Biopsy Guidance for Prostate Cancer: Fusion-Guided. BioMed Research International, 2014, 2014, 1-7.	0.9	35
205	Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. Urology Practice, 2014, 1, 13-21.	0.2	7
206	Identification of Threshold Prostate Specific Antigen Levels to Optimize the Detection of Clinically Significant Prostate Cancer by Magnetic Resonance Imaging/Ultrasound Fusion Guided Biopsy. Journal of Urology, 2014, 192, 1642-1649.	0.2	55
207	Prostate Biopsy for the Interventional Radiologist. Journal of Vascular and Interventional Radiology, 2014, 25, 675-684.	0.2	15
208	Prediction of prostate cancer Gleason score using a MRI-based nomogram Journal of Clinical Oncology, 2014, 32, 255-255.	0.8	1
209	Multiparametric prostate MRI and MRI/ultrasound fusion biopsy as tools to follow prostate cancer progression for men on active surveillance Journal of Clinical Oncology, 2014, 32, 63-63.	0.8	2
210	The performance of targeted magnetic resonance imaging/ultrasound fusion biopsy versus random 12-core biopsy for prediction of total prostate cancer tumor volume Journal of Clinical Oncology, 2014, 32, 34-34.	0.8	0
211	Comparing magnetic resonance imaging/ultrasound-fusion biopsy and systemic 12-core transrectal ultrasound biopsy for whole gland pathology Journal of Clinical Oncology, 2014, 32, 84-84.	0.8	Ο
212	Utility of multiparametric MRI at 3 tesla and MRI/ultrasound fusion-guided biopsy in detecting seminal vesicle invasion by prostate cancer Journal of Clinical Oncology, 2014, 32, 128-128.	0.8	0
213	Using MRI/ultrasound fusion biopsy to detect clinically significant prostate cancer in the African American population Journal of Clinical Oncology, 2014, 32, 57-57.	0.8	Ο
214	Utility of Multiparametric Magnetic Resonance Imaging Suspicion Levels for Detecting Prostate Cancer. Journal of Urology, 2013, 190, 1721-1727.	0.2	171
215	Magnetic Resonance Imaging/Ultrasound–Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12-core Transrectal Ultrasound Biopsy. European Urology, 2013, 64, 713-719.	0.9	436
216	Can Magnetic Resonance-Ultrasound Fusion Biopsy Improve Cancer Detection in Enlarged Prostates?. Journal of Urology, 2013, 190, 2020-2025.	0.2	73

#	Article	IF	CITATIONS
217	Fully Automated Prostate Segmentation on MRI: Comparison With Manual Segmentation Methods and Specimen Volumes. American Journal of Roentgenology, 2013, 201, W720-W729.	1.0	52
218	Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla. BJU International, 2012, 110, E694-700.	1.3	52
219	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. Journal of Urology, 2012, 188, 1157-1163.	0.2	188
220	Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies. Journal of Urology, 2012, 188, 2152-2157.	0.2	227
221	Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy Improves Cancer Detection Following Transrectal Ultrasound Biopsy and Correlates With Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2011, 186, 1281-1285.	0.2	408
222	Laparoscopic Partial Adrenalectomy. Journal of Urology, 2010, 184, 1860-1860.	0.2	3
223	Renal carcinoma: minimally invasive surgery of the small renal mass. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 335-336.	0.8	11